Growth hormone treatment and the risk of adolescent scoliosis: A large matched cohort study

Aim We aimed to evaluate the risk of developing adolescent scoliosis among recipients of recombinant human growth hormone (rhGH). Methods This registry‐based cohort study included 1314 individuals who initiated rhGH treatment since 2013, treated during 10–18 years of age for at least 6 months. This...

Full description

Saved in:
Bibliographic Details
Published in:Acta Paediatrica 2023-06, Vol.112 (6), p.1240-1248
Main Authors: Ziv‐Baran, Tomer, Modan‐Moses, Dalit, Zacay, Galia, Ackshota, Nissim, Levy‐Shraga, Yael
Format: Article
Language:English
Subjects:
Adolescent
adolescents
Child
Cohort analysis
Cohort Studies
Female
Growth Disorders - drug therapy
Growth Disorders - epidemiology
Growth hormones
Human Growth Hormone - adverse effects
Humans
Infant
Male
recombinant human growth hormone
Recombinant Proteins - adverse effects
Scoliosis
Scoliosis - complications
Scoliosis - epidemiology
side effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim We aimed to evaluate the risk of developing adolescent scoliosis among recipients of recombinant human growth hormone (rhGH). Methods This registry‐based cohort study included 1314 individuals who initiated rhGH treatment since 2013, treated during 10–18 years of age for at least 6 months. This group was matched to a comparison group of 6570 individuals not treated with rhGH. Demographic and clinical information was extracted from the electronic database. The results are presented using hazard ratios (HR) and 95% confidence intervals (CI). Results During a median follow‐up of 4.2 years, 59 (4.5%) rhGH recipients and 141 individuals (2.1%) from the comparison group were diagnosed with adolescent scoliosis. The age at diagnosis did not differ between the groups (14.7 versus 14.3 years, p = 0.095). Patients treated with rhGH were more likely diagnosed with scoliosis (HR 2.12, 95% CI 1.55–2.88, p 
ISSN:0803-5253
1651-2227
DOI:10.1111/apa.16749